Combinatorial Anti-Cancer Effect of Polypurine Reverse Hoogsteen Hairpins against KRAS and MYC Targeting in Prostate

Simonas Valiuska1,2, Kayla K Elder3, Steven J McKay3

  • 1Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, University of Barcelona (UB), 08028 Barcelona, Spain.

Genes
|October 26, 2024
PubMed

Insights

Targeting KRAS and MYC proto-oncogenes with Polypurine Reverse Hoogsteen (PPRH) hairpins synergistically reduced cancer cell viability. This dual gene modulation approach effectively decreased cell proliferation and expression of these key cancer-driving genes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • KRAS and MYC are proto-oncogenes crucial for cell growth and proliferation.
  • Dysregulation of KRAS and MYC is linked to cancer progression.
  • Previous studies individually targeted these oncogenes using Polypurine Reverse Hoogsteen (PPRH) hairpins.

Purpose of the Study:

  • To investigate the cooperative dynamics between KRAS and MYC.
  • To evaluate the combined impact of PPRHs targeting both KRAS and MYC in pancreatic and prostate cancer cells.

Main Methods:

  • Utilized Polypurine Reverse Hoogsteen (PPRH) hairpins to target KRAS and MYC oncogenes.
  • Assessed transcriptional and translational modulation of oncogenes.
  • Evaluated cell viability and cytotoxicity in cancer cell lines.

Main Results:

  • Combined PPRH treatment modulated the expression of both KRAS and MYC, leading to downregulation.
  • MYC-targeting PPRHs, particularly HpMYC-G4-PR-C, showed significant cytotoxic and expression modulation effects.
  • Synergistic reduction in cancer cell viability was observed when both KRAS- and MYC-targeting PPRHs were applied concurrently.

Conclusions:

  • Simultaneous targeting of KRAS and MYC with PPRHs is an effective strategy for gene modulation.
  • This combined approach demonstrates efficacy in decreasing cancer cell proliferation and viability.
  • The findings support the potential of dual oncogene targeting in cancer therapy.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K